Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment the Government has made of the potential for additional costs or complexities for medicines manufacturers in securing separate regulatory approval for products for the UK and the EU after the UK leaves the EU.

The Government is fully assessing how the United Kingdom’s decision to leave the European Union will impact on medicines regulation in the UK. No decision has yet been made on the future of UK medicines regulation. Therefore, we cannot speculate on future regulatory processes or costs for medicines manufacturers.